Breaking Down Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Financial Health: Key Insights for Investors

Tonghua Golden-Horse Pharmaceutical's recent performance is a study in contrasts: first nine months of 2025 sales fell to CNY 892.25 million from CNY 968.59 million a year earlier and full-year 2024 revenue dropped to CNY 1.32 billion (down 10.23% year-over-year), yet net income for 2024 rose to CNY 56.44 million (up 28.46%), while market capitalization surged to CNY 24.37 billion as of October 29, 2025 (a 79.05% increase year-over-year) and the stock is up 45.33% over 52 weeks; beneath those headlines lie mixed profitability signals-TTM net profit margin ~4.3%, operating margin 8.21%, gross margin 74.35%, ROE 2.62% and ROA 2.03%-and balance-sheet tensions with total debt of CNY 1.86 billion vs. cash CNY 344.76 million, a debt-to-equity of 0.82, current ratio 0.58 and quick ratio 0.41, yet an Altman Z-Score of 3.53 and Piotroski F-Score of 5; valuation metrics show elevated expectations with a trailing P/E of 423.91, P/B of 10.03, EV/EBITDA 114.37 and EV/FCF 146.23, while growth levers include overseas revenue of CNY 110 million in H1 2025 and progress on insulin and GLP-1 registrations-read on to dissect the numbers, risks and catalysts in detail.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Revenue Analysis

• Full-year revenue 2024: CNY 1,320.00 million (down 10.23% from CNY 1,470.00 million in 2023).
• Net income 2024: CNY 56.44 million (up 28.46% vs. prior year; implied 2023 net income ≈ CNY 43.93 million).
• First nine months 2025 revenue: CNY 892.25 million (vs. CNY 968.59 million for the same period in 2024).
• Primary near-term revenue headwinds: insulin procurement price reductions and inventory adjustments by commercial customers.

• Operational implications: revenue contraction concentrated in product/contract pricing and channel inventory; margin recovery produced higher net income despite lower top line.
• Market signal: substantial market-cap growth (+79.05% over 1 year) and strong 52-week share appreciation (+45.33%) indicate investor confidence despite near-term sales weakness.
• Reference for corporate direction: Mission Statement, Vision, & Core Values (2026) of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Profitability Metrics

The following key profitability indicators summarize Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's recent performance and efficiency in converting revenue into earnings.

• Net income (First 9 months 2025): CNY 24.96 million (vs CNY 23.92 million in first 9 months 2024)
• Net profit margin (TTM): 4.3%
• Operating margin (TTM): 8.21%
• Gross margin: 74.35%
• Return on equity (ROE): 2.62%
• Return on assets (ROA): 2.03%

• Revenue-to-profit conversion shows room for margin expansion despite high gross margins.
• Operating margin suggests management has controlled operating expenses relative to revenue.
• ROE and ROA indicate modest returns relative to equity and asset base, signaling potential leverage or reinvestment impacts.

For additional corporate context and strategic orientation, see Mission Statement, Vision, & Core Values (2026) of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Debt vs. Equity Structure

• Leverage: A debt-to-equity ratio of 0.82 signals moderate leverage - debt is meaningful but not extreme relative to equity.
• Liquidity pressure: Current ratio 0.58 and quick ratio 0.41 both point to potential difficulty meeting short-term obligations without converting long-term assets or raising funds.
• Interest serviceability: Interest coverage of 1.72 indicates operating income covers interest expenses by a modest margin, leaving limited cushion for earnings volatility.
• Net debt magnitude: Net debt of ~CNY 1.52 billion is material and should be monitored against free cash flow generation and refinancing timelines.
• Cash buffer: The company's cash balance (CNY 344.76 million) provides operational flexibility; the company's net cash position provides operational flexibility and resilience in a capital-intensive industry.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Liquidity and Solvency

• Short-term liquidity: Current ratio 0.58 and quick ratio 0.41 indicate reliance on non‑current funding or inventory conversion to meet working capital needs.
• Interest servicing: With an interest coverage ratio of 1.72, operating income covers interest expense but leaves limited buffer versus cyclicality or margin pressure.
• Bankruptcy risk: Altman Z‑Score of 3.53 signals low probability of bankruptcy, supporting medium‑term solvency confidence.
• Fundamental quality: Piotroski F‑Score of 5 points to mixed operational/earnings improvements - neither strong nor weak overall.

• Operational flexibility is supported by a positive net cash position despite tight working capital ratios.
• Monitor receivables, inventory turnover and short-term borrowings to assess whether current/quick ratios improve or liquidity pressure increases.
• Given narrow interest coverage, rising interest rates or declining margins could materially tighten financial stress.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Valuation Analysis

• Trailing P/E: 423.91 - investors are pricing in substantial future earnings growth or very low current EPS base.
• P/B: 10.03 - the stock trades well above book value, signaling high investor confidence or heavy intangible asset valuation.
• EV/EBITDA: 114.37 - a steep multiple versus earnings before non-cash and financing items, implying rich enterprise valuation.
• EV/FCF: 146.23 - the enterprise value relative to free cash flow is elevated, indicating scarce FCF or high growth premium.
• Market capitalization (as of 2025-10-29): CNY 24.37 billion - a 79.05% increase year-over-year.
• 52-week price change: +45.33% - strong recent price appreciation and positive market sentiment.

• Interpretation considerations:
  • High multiples necessitate corroboration from revenue growth, margin expansion, and cash generation.
  • Compare with peer group biotech/pharma multiples to contextualize premium.
  • Monitor EPS trajectory and free cash flow conversion to justify current valuation.
• Research pointer: for company background, ownership and how it generates revenue see Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd: History, Ownership, Mission, How It Works & Makes Money

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Risk Factors

• Regulatory and policy risk: Operating in China's pharmaceutical sector exposes the company to lengthy drug approval cycles (NMPA reviews), centralized procurement and price-pressure mechanisms. Past waves of centralized procurement and NRDL (National Reimbursement Drug List) adjustments have compressed prices across the industry, and any negative regulatory action or delayed approval for core products could materially reduce near-term revenue.
• Competitive pressure: The company competes with large domestic groups and multinational pharmaceutical companies that have deeper R&D budgets, broader commercialization networks and stronger pricing leverage. Market-share erosion on key product lines is a consistent downside risk.
• Financial volatility and historical losses: Tonghua Golden-Horse has shown episodic volatility in operating results, including periods with compressed gross margins and occasional net losses in prior reporting periods. Investors should anticipate earnings variability tied to product launches, one-off impairment charges and R&D spending cycles.
• Debt and liquidity opacity: Public English-language disclosures do not always provide full transparency into the maturity profile of on- and off-balance-sheet liabilities. This creates uncertainty around refinancing risk, interest coverage and short-term liquidity - especially if working capital needs rise unexpectedly.
• Supply-chain dependency: The business relies on third-party suppliers for active pharmaceutical ingredients (APIs) and packaging materials. Disruptions from raw-material shortages, quality-control issues, or import/export constraints (including tariff and logistics changes) can delay production and increase costs.
• Capital allocation and dividend policy: The company follows a zero-dividend policy, retaining earnings for operations, R&D and expansion. While this supports reinvestment, it limits near-term cash returns to shareholders and places greater emphasis on management's capital-allocation efficacy.

• Quantitative indicators investors should monitor:
  • Top-line trends: sequential and YoY revenue growth for core therapeutic lines and hospital sales channels.
  • Profitability: gross margin and adjusted net margin volatility over rolling 4-quarter periods.
  • Leverage measures: total debt / equity and interest coverage ratio (EBITDA / net interest expense).
  • Cash conversion: operating cash flow relative to net income and changes in working capital.
  • R&D cadence and capital expenditures: annual R&D spend as % of revenue and committed capex.
• Event triggers that could materially change risk profile:
  • Inclusion/exclusion of key products from NRDL or provincial procurement lists.
  • Major regulatory approval or rejection of a late-stage product.
  • Announcements of strategic partnerships, licensing deals, or large-scale M&A.
  • Material changes in debt terms, refinancing outcomes, or new capital raises.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) - Growth Opportunities

• Product portfolio expansion: management emphasis on new drug development and widening TCM and biologics offerings.
• Production capability enhancements: ongoing upgrades to manufacturing lines to support larger-scale launches and export compliance.
• Regulatory catalysts: potential upside from upcoming earnings releases and approvals for insulin and GLP‑1 candidates (timing subject to regulatory review).
• Market demand tailwinds: structural growth in China's healthcare spending and supportive government pharmaceutical initiatives.
• International commercialization: active overseas applications and registrations with tangible progress in insulin and GLP‑1 programs.

• Investor sentiment: market cap appreciation of 79.05% over the past year reflects strong investor confidence and raises expectations for continued top‑line and margin improvement.
• Commercial inflection: H1 2025 overseas revenue of CNY 110m is an early signal that international commercialization can materially contribute to revenue growth if regulatory and market execution continue.
• Potential valuation drivers: successful approvals for insulin/GLP‑1 products, sustained domestic demand for TCM/biologics, and scaling export revenue.